CJC-1295 / Ipamorelin: Two Receptors, One GH Pulse

The short version

CJC-1295/Ipamorelin is not one peptide but two, typically dosed together. CJC-1295 is a modified, long-acting version of growth hormone-releasing hormone (GHRH) — it locks onto a carrier protein in the blood so its GH-boosting signal lasts for days instead of minutes. Ipamorelin is a much smaller peptide that works through a different switch, the ghrelin receptor, to trigger its own short burst of GH release. The idea behind pairing them is that two different 'on' switches for the same hormone should add up to more growth hormone than either alone.

That idea has real support at the level of cells in a dish ^[5] and from studies of each peptide separately ^[2][3][4]. What doesn't exist is a published human trial of the fixed CJC-1295 + ipamorelin combination itself. This page lays out what is actually known, separates it clearly from what is assumed, and does not suggest a dose for anyone.

What it is

CJC-1295 is a synthetic analogue of the first 29 amino acids of human growth hormone-releasing hormone (hGRF 1-29), modified at four positions to resist enzymatic breakdown. The version most often meant by 'CJC-1295' in research-use marketing carries a Drug Affinity Complex (DAC) — a small chemical arm that forms a covalent bond with a cysteine on circulating albumin, effectively hitching the peptide to a very long-lived blood protein ^[4]. That bond is what stretches its action from the minutes-long half-life of natural GHRH to multiple days ^[3]. A 'no-DAC' version, often marketed as Mod GRF (1-29), lacks this feature and behaves more like a short-acting GHRH fragment.

Ipamorelin is a five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) engineered to activate the ghrelin receptor (GHS-R1a) selectively, without meaningfully touching the receptors older secretagogues affected.

How it works

CJC-1295 binds the GHRH receptor on pituitary somatotrophs, a class-B G-protein-coupled receptor that signals through cAMP to drive GH synthesis and release. Ipamorelin binds a separate receptor, GHS-R1a, signaling instead through calcium mobilization. Because the two pathways are structurally independent, activating both at once produces a GH response that cell studies show is roughly double what GHRH-receptor activation alone produces — direct evidence of receptor-level cross-talk between the two systems ^[5].

In principle, this is why the two peptides are combined rather than used alone: pairing a sustained GHRH-receptor signal with a repeatable ghrelin-receptor pulse aims to raise both the amplitude and frequency of GH pulses, with IGF-1 rising as a downstream consequence. Whether that theoretical additive effect actually plays out as intended in a person taking both peptides together has not been measured in any published trial.

What the research shows

Because no trial has tested the CJC-1295/ipamorelin blend directly, the strongest available evidence comes from each half studied separately, plus a related GHRH analogue used as a read-across data point.

A 2026 meta-analysis of five randomized controlled trials of tesamorelin — a different, already-marketed GHRH analogue — found significant reductions in visceral fat (mean difference -27.71 cm²) and liver fat (-4.28%), along with increased lean body mass (+1.42 kg) and IGF-1, with no serious adverse events or disrupted blood sugar ^[1]. This is context for what GHRH-receptor stimulation in general can do, not data on CJC-1295 itself.

A single dose of CJC-1295 with DAC raised GH two- to ten-fold for six or more days and IGF-1 by 1.5- to threefold for nine to eleven days in healthy adults; with repeated dosing, IGF-1 stayed elevated for up to 28 days ^[3]. In rats, the DAC modification produced roughly four times the GH exposure of unmodified GHRH over two hours, with albumin-bound peptide still detectable in blood after 72 hours ^[4].

A broader review of growth hormone secretagogues as a drug class found them generally well tolerated, with the main concern being a modest rise in blood glucose from reduced insulin sensitivity, and noted that long-term cancer and mortality data are still missing ^[2]. At the receptor level, co-activating cloned GHRH and ghrelin receptors in transfected cells produced roughly double the cAMP signal of GHRH-receptor activation alone ^[5].

Reported effects, cautions & safety

People discussing the CJC-1295 + ipamorelin stack in research-use communities describe a fairly consistent pattern — this is anecdotal, not clinical evidence, drawn from online reports rather than measured trial outcomes, and no dose is implied by repeating it.

Reported benefits: deeper, more restorative sleep is the most frequently mentioned effect, often noticed within one to two weeks. Faster workout recovery and reduced next-day soreness are also commonly described, frequently grouped with other recovery-focused peptides. Gradual fat loss over five or more weeks, subtly improved skin/nail/hair 'feel', better mood and energy, and increased appetite in the hours after dosing (from ipamorelin acting on the ghrelin receptor) round out the frequently reported cluster.

Reported adverse effects: injection-site redness or itching is the most consistently mentioned complaint. Transient water retention, a brief facial flush or head-rush after dosing, occasional tingling or carpal-tunnel-like hand symptoms, lethargy, and lightheadedness are also described, generally as mild and easing with continued use.

Cited cautions: growth hormone drives IGF-1, a known mitogen, so an active or recent malignancy is a mechanistic concern, even though the fixed blend has never been tested for tumor-promoting effects ^[3]. The secretagogue class as a whole carries a documented risk of reduced insulin sensitivity and higher blood glucose ^[2]. The blend itself has never been studied in a controlled trial, and its two halves work on mismatched timescales — CJC-1295 DAC lasting days, ipamorelin clearing within hours — meaning the intended pulsatile synergy is not characterized for any specific protocol ^[3][4]. GH excess is separately linked to fluid retention, carpal-tunnel-type nerve compression, and joint pain ^[2][3]. No regulator has approved either compound, and long-term human safety data for the pair do not exist ^[2].

Where it fits in the Growth Hormone Axis

CJC-1295/Ipamorelin is this desk's dual-receptor entry: a long-acting GHRH-receptor signal paired with a repeatable ghrelin-receptor pulse, aimed at the pituitary's two independent GH-release switches. Sermorelin is the simpler, single-receptor comparison — a GHRH analogue alone, with by far the deepest clinical trial record of the three. MOTS-c sits outside this receptor logic entirely, working through mitochondrial and cytosolic pathways rather than the pituitary. Reading the three together clarifies what a second receptor arm is thought to add, and how much of that addition is inferred rather than measured. See the comparison page for the side-by-side.